ReviewClinical microbiology reviews2016
Fosfomycin.
Review in Clinical microbiology reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05055544 (BeaRberry in the Treatment of Acute UncoMplIcated Cystitis), which is not on this map. Cited by 312 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BeaRberry in the Treatment of Acute UncoMplIcated Cystitis (BRUMI)- Protocol of a Multicentre, Randomized Double-Blind Clinical Trial
Who cites it
312 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- Updated antimicrobial dosing recommendations for obese patients.Antimicrobial agents and chemotherapy · 2024Pooled it
- Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis.World journal of urology · 2024Pooled it
- [Microbial etiology of bacterial chronic prostatitis: systematic review].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Pooled it
- Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Pooled it
- Trial
- Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial.Nature medicine · 2023Trial
- Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Real-World Data on the Effectiveness and Use of Intravenous Fosfomycin for the Treatment of Difficult-to-Treat Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria-A Subgroup Analysis from the FORTRESS Study.Infectious diseases and therapy · 2026Article
- Embedding locally tailored antimicrobial prophylaxis into standardized order sets for urological procedures reduces antimicrobial use.JAC-antimicrobial resistance · 2026Article
- Decoding the genomic repertoire of fosfomycin resistance genes in staphylococci.Nature communications · 2026Article
- Heterogeneity in the response to the metabolic environment drives fosfomycin heteroresistance.Nature communications · 2026Article
- Real-World Data on the Use of Intravenous Fosfomycin for the Treatment of Central Nervous System Infections: a Subgroup Analysis from the FORTRESS Study.Infectious diseases and therapy · 2026Article
- What's in a Name? Etymology and History of Antibacterials and Antifungals.Open forum infectious diseases · 2026Review
- Liposome-Mediated Bacterial Ferroptosis-like Death: A Novel Paradigm for Antimicrobial Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review.Infection · 2026Review
- Fosfomycin Resistance Dynamics in Major Uropathogens: A 2013-2025 Integrated Disease Surveillance of Multidrug-Resistant, Extended-Spectrum Beta-Lactamase-Producing, Non-Extended-Spectrum Beta-Lactamase, and Enterococcal Urinary Isolates.Pathogens (Basel, Switzerland) · 2026Article
- Fosfomycin susceptibility and molecular detection of fosA-mediated resistance among gram-negative uropathogens from a tertiary care hospital in Lucknow, India.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Fosfomycin Resistance in Escherichia coli: Mechanisms, Trends, and Clinical Challenges.Cureus · 2026Review
252 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria. As a result, physicians have turned to older antibiotics, such as polymyxins, tetracyclines, and aminoglycosides. Lately, due to development of resistance to these agents, fosfomycin has gained attention, as it has remained active against both Gram-positive and Gram-negative MDR and XDR bacteria. New data of higher quality have become available, and several issues were clarified further. In this review, we summarize the available fosfomycin data regarding pharmacokinetic and pharmacodynamic properties, the in vitro activity against susceptible and antibiotic-resistant bacteria, mechanisms of resistance and development of resistance during treatment, synergy and antagonism with other antibiotics, clinical effectiveness, and adverse events. Issues that need to be studied further are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.